A leading global rail-transportation OEM replaced multi-week autoclave validation trials with one continuous test — capturing $284K in direct annual savings (142% ROI, payback inside nine months), and another ~$120K savings from standardization and energy reduction.
Fewer days per cure validation cycle
Direct annual savings
Payback period
- Cure validation cycle time dropped from ~15 days to one day or less — a 93% reduction
- Direct, hard-dollar annual savings: $284,000 across validation, scrap, time-to-market, and rework. Against a ~$200K investment, that delivers 142% ROI in year one with payback inside nine months
- Additional annual value as the program scales: ~$120,000 from standardization and compounding energy savings
- Total value: ~$404,000 of annual value capture, ~200% return as the standardization and energy benefits emerged
- The customer is now among the first ESR adopters in rail-transportation composites and a co-author of the testing standard the rest of the industry will inherit
A leading global rail-transportation manufacturer — one of the largest rolling-stock OEMs in the world and the company behind several of the most advanced next-generation rail platforms in operation today — needed cure data that aligned with production realities. Conventional DSC, DMA, and open-plate rheometry weren’t giving them the confidence they wanted. In 2024, after a multi-meeting technical exchange with our applications engineering team, the customer deployed the Premier Encapsulated Sample Rheometer (ESR), which meets ASTM D7750. Twelve months later, the picture is clear.
Four Instruments, Four Stories, None Matching the Autoclave
The customer is pioneering the use of advanced composites in train car body structures, with the goal of replacing metal components with lightweight epoxy, phenolic, and polyester systems processed via prepreg autoclave and VARTM molding. These aerodynamic shells depend on this work.
The lab they relied on to support the program inherited a familiar problem: every instrument they had — DSC, DMA, conventional rheometers — told a slightly different story, and none of those stories matched what happened inside the autoclave. Four pain points dominated:
Sample-scale mismatch
DSC operates on milligram samples in open pans. That tells you reaction chemistry, but it can’t represent fiber-rich prepreg under pressure.
Multi-week validation loops
Each cure cycle change required a full autoclave trial, technician time, and destructive physical property testing — roughly 15 days, end to end.
Tg data that wouldn’t reconcile
Glass transition temperatures from DSC and DMA disagreed often enough that engineers couldn’t confidently sign off on cure completion.
No industry standard
Unlike aerospace, the rail composite sector has had no agreed protocol for resin and prepreg cure testing. The customer was being asked to lead an industry without a yardstick.
In a market where every additional week of validation pushes program delivery and every conservative cure-cycle safety margin adds energy cost, scrap risk, and time to revenue, the gap between lab data and production reality was an unacceptable structural drag.
One Sealed-Cavity Test That Matches the Autoclave
The Premier ESR is built around ASTM D7750, the standard method for measuring viscoelastic property evolution during cure inside a sealed, pressurized, thermally faithful test cavity. Where DSC infers cure from heat flow on a milligram sample, ESR measures the actual progression of storage modulus (G′), loss modulus (G″), and tan δ on a production-representative specimen under conditions that mirror the autoclave. For this customer, four capabilities turned out to matter most:
Real-world simulation of the cure cycle
Sealed cavity, direct die heating, controlled pressure — lab conditions that finally look like the autoclave.
Cure kinetics and Tg from a single test
No more reconciling DSC against DMA. One specimen, one continuous record, one defensible Tg.
Drastically compressed validation time
Iteration moves from autoclave shop to lab bench.
A path to standardization
ASTM D7750 anchors the protocol; the customer builds the rail-specific layer on top.
- ~15 days per cure validation trial
- Autoclave time consumed for each iteration
- DSC small-sample data not representative of production
- Tg results inconsistent across DSC and DMA
- No standardized rail-industry cure protocol
- Confidence in scale-up: low
- ~1 day per validation — lab-only, no autoclave needed
- Real-world simulation under sealed, pressurized cure
- Cure kinetics and Tg captured in one continuous test
- ASTM D7750 — auditable, reproducible, defensible
- The customer pioneering the rail-industry test standard
- Confidence in scale-up: production-ready
$284K of Direct Savings, With Additional Upside
The main finding from the customer’s twelve-month review with our applications engineering team is that validation cycle time dropped from approximately 15 days per trial to a single day.
At ~20 cure validation cycles per year, the per-cycle cost difference from technician time, autoclave utilization, materials, destructive testing translates directly into the largest line item in the value capture below.
We separate the value into two tiers: direct, hard-dollar savings that the customer is realizing now and that anchor the ROI and payback math; and additional gains that include standardization leadership and compounded energy savings. These are real but realize over a longer horizon and at lower confidence.
| Value category | Estimated annual value (USD) |
|---|---|
| Validation cycle savings (20 cure trials × ~$10K saved each) | $198,000 |
| Material scrap reduction during scale-up | $16,000 |
| Faster time-to-market across major composite programs | $60,000 |
| Reduced rework on out-of-spec prepreg batches | $10,000 |
| Direct savings subtotal — 142% Year-1 ROI, payback <9 months | $284,000 |
| Additional gains (not included in payback calculation) | |
| Standardization leadership premium (early ESR adopter in rail composites) | $60,000 |
| Energy and emissions value from compounded cure-cycle reduction | $60,000 |
| Additional gains subtotal | $120,000 |
| All-in annual value as program scales | ~$404,000 |
On a ~$200K investment, $284K of direct annual savings delivers a 142% return in year one with payback achieved in approximately eight months. As the additional gains compound across more programs and more cure cycles, the all-in trajectory points toward ~$404K of annual value capture, ~200% return, which includes the standardization premium and energy benefits.
More Than a Capital Purchase
The strategic case is what makes this engagement different from a typical capital purchase.
An early-adopter lead
The customer is now among the first ESR adopters in rail-transportation composites. That position carries durable advantages: shorter qualification cycles for new resin systems, faster onboarding of additional prepreg suppliers, and a measurable lead on competitors still working from non-representative cure data.
Co-authoring the industry protocol
Together with our applications engineering team, the customer is developing rail-specific testing standards built on the ASTM D7750 foundation. The first publications are scheduled for major composite-industry conferences. Companies that follow will, by definition, be following the standard this customer is helping to write.
Metal-to-composite roadmap
Every weight reduction unlocked by composite substitution improves energy efficiency across the rail platform. And every cure cycle that runs tighter, with less scrap and less rework, compounds those gains.
ESR fills a critical gap in our ability to measure and control prepreg curing. It aligns perfectly with our goals to standardize composite testing and reduce development time.
R&D Team
Leading global rail-transportation OEM
Turn the cure cycle into an engineering variable
This story is the rail-transportation version of a pattern we see across composite-intensive industries. Conservative cure recipes persist because cure data is conservative. Process engineers default to overcure because they don’t fully trust what the lab is telling them. Energy, time, scrap, and capital all pay the price.
Production-representative cure characterization using ESR run under ASTM D7750 turns the cure cycle from a fixed empirical recipe into a controllable engineering variable. The companies that close this gap will get to scale-up faster, with less waste, with better ESG performance, and with the data trail that auditors, OEM customers, and capital markets are increasingly requiring.
Optimizing Cure with the ESR
Troubleshooting prepreg failures with the Encapsulated Sample Rheometer. Inside the study: how five processing parameters drive the difference between a confident cure cycle and an unpredictable one.